Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-23-075821
Filing Date
2023-06-28
Accepted
2023-06-28 16:30:10
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2320004d1_defa14a.htm DEFA14A 14989
2 GRAPHIC tm2320004d1_defa14aimg01.jpg GRAPHIC 5654
  Complete submission text file 0001104659-23-075821.txt   24157
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33357 | Film No.: 231052602
SIC: 2836 Biological Products, (No Diagnostic Substances)